We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Eagle Pharmaceuticals and AMRI Announce Agreement

News   Jan 14, 2016

 
Eagle Pharmaceuticals and AMRI Announce Agreement
 
 
 

RELATED ARTICLES

Clinical Trial Assessing Treatments for Preventing People at High Risk From Developing Multidrug-resistant TB Launches

News

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

READ MORE

Sickle Cell Drug IMR-687 Shows Promise in Clinical Trial

News

An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.

READ MORE

Patent Issued for Osteoarthritis Gene Therapy Product

News

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE